 The purpose of this study is to investigate whether in patients with chronic HBeAg-negative hepatitis B, PEG-IFN-ribavirin combination therapy for 1 year leads to enhanced response HBV DNA 10E4 copiesml and normal ALT 24 weeks after treatment discontinuation in comparison with pegylated interferon PEG-IFN monotherapy. 